Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or natasha@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
natasha@zenopa.com
+44 1494 818 053

Testimonials
I just wanted to say thank you very much for all your help over the months to find me a position. I would definitely use Zenopa again and would always recommend you to others.
Marie, 2013

GlaxoSmithKline reports positive phase III data for HIV drug

11 July 2012 11:26 in Pharmaceutical Company Product News


GlaxoSmithKline has unveiled encouraging clinical trial data for the once-daily HIV treatment dolutegravir via Shionogi-ViiV Healthcare.

The integrase inhibitor demonstrated superiority in a phase III study against the market-leading drug Atripla, which is manufactured by Gilead.

At 48 weeks, 88 percent of study participants taking dolutegravir were virologically suppressed, compared with 81 percent of patients using Atripla.

Shionogi-ViiV Healthcare is a joint venture between Japanese pharmaceutical firm Shionogi and ViiV, the company set up by GlaxoSmithKline and Pfizer in 2009 to focus on HIV treatments.

Dr John Pottage, chief medical officer at ViiV Healthcare, described the phase III data for dolutegravir as "an important milestone in the development of dolutegravir-based regimens, including a single-tablet regimen, and also for the Shionogi-ViiV Healthcare joint venture".

Full results of the study, which is the second of four phase III trials of the drug being completed this year, are due to be presented at forthcoming scientific meetings.ADNFCR-8000103-ID-801404909-ADNFCR

Other news stories from 11/07/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2015 Zenopa Ltd